
- Gastrointestinal Cancers: mCRC (Issue 9)
- Volume 1
- Issue 9
Impact of HER2 Amplification in Colorectal Cancer
Kanwal Raghav,MBBS, MD, Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, the University of Texas M.D. Anderson Cancer Center, discusses HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer.
Kanwal Raghav,MBBS, MD, Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, the University of Texas M.D. Anderson Cancer Center, discusses HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer.
Articles in this issue
almost 10 years ago
Role of DPR in Colorectal Canceralmost 10 years ago
Overview of the Lume 1 and 2 Trialsalmost 10 years ago
Tumor Location Findings Shed Light on CALGB/SWOG 80405, FIRE-3 Discrepancyalmost 10 years ago
Novel Immunotherapy Combinations on Horizon for mCRCalmost 10 years ago
SIRT Added to First-line Chemo Improves Response in Colorectal Cancer






























